Skip to main content

Table 4 Selenium supplementation studies in patients who underwent radiotherapy

From: Updates on clinical studies of selenium supplementation in radiotherapy

Study no. Reference Type of cancer/disease Type of study Form of Se used for supplementation Dose (μg) Administration Items observed/measured Result
11 Pakdaman, [27] Brain tumor Not mentioned Sodium selenite 1000/day (4–8 weeks) Infusion (during radiotherapy) Mineral elements, Se and other blood parameters (AST, ALT, γ-GTP, ESR) A significant diminution of symptoms of intracranial pressure was achieved in 76% of patients.
12 Kiremidjian-Schumacher et al. [28] Head and neck cancer Randomized double-blind placebo-controlled study Sodium selenite 200/day (8 weeks) Oral (during radiotherapy) Se in plasma, CTL, MLR, PHA Significantly enhanced cell-mediated immune responsiveness
13 Micke et al. [29] Secondary Lymphedema Not mentioned Sodium selenite 500/day (4–6 weeks) Oral (4 or10 months after radiotherapy) Foldi and Miller scoring and quality of life Foldi and Miller score: more than 78% showed an improvement of one stage or more
14 Elango et al. [30] Oral cancer Not mentioned Sodium selenite 400/day (6 months) Oral (during radiotherapy) Plasma Se, enzymatic (GPx and others) and non-enzymatic antioxidants Supplementation increased the enzymatic and non enzymatic defense systems
15 Muecke et al. [31] Cervical cancer (n = 11); Uterin cancer (n = 70) Multicenter, phase 3 trial Sodium selenite 500 or 300/day Oral (during radiotherapy) Whole blood Se Statistically significant in reducing the number of episode and severity of RT-induced diarrhea
16 Buntzel et al. [32] Head and neck (n = 39) Randomized phase II study Sodium selenite 500 or 300/day Oral (during radiotherapy) Side effect evaluation Reduced the development of dysphagia due to radiotherapy